<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039181</url>
  </required_header>
  <id_info>
    <org_study_id>P-09-00171</org_study_id>
    <nct_id>NCT01039181</nct_id>
  </id_info>
  <brief_title>Calcitriol in Advanced Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>A Clinical Trial Phase II of Calcitriol in Combination With 5-fluorouracil, Mitomycin C and Leucovorin in an Open Label-non-randomized Study to Evaluate the Tumor Response in Patients With Advanced Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Science and Technology Development Agency, Thailand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Science and Technology Development Agency, Thailand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholangiocarcinoma (CCA), cancer of the bile duct, is the first cause of cancer death of the&#xD;
      people in the northeast of Thailand. The incidence of CCA in this region is highest not only&#xD;
      in the country but in the world. CCA is a slow growing but highly metastatic tumor. At&#xD;
      present, there is no standard chemotherapy or effective treatment for CCA. Most of the&#xD;
      patients have short survival after diagnosis. Strong evidences from in vitro, animal and&#xD;
      clinical studies indicate that vitamin D can prevent and control growth of cancer. Our&#xD;
      preclinical studies in CCA cell lines, animal and patient tissue culture indicate that&#xD;
      vitamin D effectively reduce growth of CCA. Supplementation of vitamin D to chemotherapeutic&#xD;
      drugs enhance drug toxicity and better response. At present, there are several clinical&#xD;
      trials in USA on supplementation of vitamin D or its analogs to cancer patients. The side&#xD;
      effect or toxicity of using vitamin D supplementation is low, some patients had stable&#xD;
      disease and some had good response. The current study is set up a clinical trial phase II of&#xD;
      vitamin D (calcitriol) in combination with 5-fluorouracil, Mitomycin C and Leucovorin in an&#xD;
      open label-non-randomized study to evaluate the tumor response in patients with advanced&#xD;
      intrahepatic cholangiocarcinoma. This study will provide an alternative/effective&#xD;
      chemotherapy treatment for CCA patients. Better survival and improved quality of life are&#xD;
      also expected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  OUTLINE: This is a dose-limiting toxicity study of calcitriol.&#xD;
&#xD;
        -  EVALUAITON: During the initial phase, 14 patients will be accrued for this study. If the&#xD;
           number of patient's response to calcitriol and 5-fluorouracil/mitomycin C/leucovorin is&#xD;
           less than 1/14, the study will be stopped. However there is one patient who responses to&#xD;
           calcitriol and 5-fluorouracil/mitomycin C/leucovorin, the new 14 patients will be&#xD;
           accrued during the secondary phase of study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability of calcitriol in combination with 5-fluorouracil/mitomycin C/leucovorin.</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess quality of life (QOL) of patients who are received calcitriol in combination with 5-fluorouracil/mitomycin C/leucovorin.</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the response of calcitriol in combination with 5-fluorouracil/mitomycin C/leucovorin in patients with advanced intrahepatic cholangiocarcinoma.</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Advanced Intrahepatic Cholangiocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).</description>
    <other_name>vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Proven histological or cytological diagnosis of advanced intrahepatic&#xD;
             cholangiocarcinoma (stage III, IV); Patients are ineligible for surgery.&#xD;
&#xD;
          2. Patients must have measurable or evaluable disease.&#xD;
&#xD;
          3. Age between 30-65 years&#xD;
&#xD;
          4. Performance status must be ECOG 0-1.&#xD;
&#xD;
          5. No prior use of chemotherapy or palliative radiation&#xD;
&#xD;
          6. Tumor size by CT scan must be larger than 10 mm.x10 mm.&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Adequate bone marrow, hepatic, and renal function, as evidenced by the following: WBC&#xD;
             &gt; 3.0 x 109/L, neutrophils &gt; 1.5 x 109 /L; platelet count &gt; 100 x 109/L; Hct &gt; 30%;&#xD;
             total bilirubin &lt; 1 mg/dL; Liver enzymes (alkaline phosphatase, AST, ALT) &lt; 3 times&#xD;
             the upper limit of the normal range. Creatinine within the normal range.&#xD;
&#xD;
          9. Female patients must not be pregnant; they must be post-menopausal or practicing an&#xD;
             accepted form of birth control. If pregnancy is a possibility, a pregnancy test will&#xD;
             be required prior to initiation of therapy.&#xD;
&#xD;
         10. Patients must be accessible for treatment and follow-up.&#xD;
&#xD;
         11. Patient and investigator signed study-specific consent form, indicating the&#xD;
             investigational nature of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to Vitamin D, 5-fluorouracil, mitomycin C&#xD;
&#xD;
          2. Hypercalcemia (patients with corrected serum calcium &gt; 10.5 mg/dL) and&#xD;
             hyperparathyroid&#xD;
&#xD;
          3. History of renal/bladder stones&#xD;
&#xD;
          4. History of nephrectomy&#xD;
&#xD;
          5. 30 days prior to study entry, CT scan or ultrasound shows renal/bladder stones.&#xD;
&#xD;
          6. Patients with congestive heart failure or arrhythmia or unstable angina within 6&#xD;
             months prior study&#xD;
&#xD;
          7. Pregnancy/Lactation&#xD;
&#xD;
          8. Palliative radiation or adjuvant therapy or chemotherapy in tumor area&#xD;
&#xD;
          9. No other concurrent malignancies&#xD;
&#xD;
         10. No active infection&#xD;
&#xD;
         11. Metastasis at central nervous system&#xD;
&#xD;
         12. Metastasis at Bone&#xD;
&#xD;
         13. Renal insufficiency (creatinine &gt; 1.5 mg/dL)&#xD;
&#xD;
         14. Patients who are in other concurrent cancer clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vajarabhongsa Bhudisawasdi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Faculty of Medicine, Liver fluke and cholangiocarcinoma research center, Khon Kaen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vajarabhongsa Bhudisawasdi, MD</last_name>
    <phone>66-43-348393</phone>
    <email>JOEVAJARA@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sopit Wongkham, PhD</last_name>
    <phone>66-43-348386</phone>
    <email>Sopit@kku.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Srinagarind Hospital, Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Vajarabhongsa Bhudisawasdi, MD</last_name>
      <phone>66-43-348393</phone>
      <email>JOEVAJARA@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sopit Wongkham, PhD</last_name>
      <phone>66-43-348386</phone>
      <email>Sopit@kku.ac.th</email>
    </contact_backup>
    <investigator>
      <last_name>Vajarabhongsa Bhudisawasdi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>December 23, 2009</last_update_submitted>
  <last_update_submitted_qc>December 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vajarabhongsa Bhudisawasdi</name_title>
    <organization>Department of Surgery, Faculty of Medicine, Liver fluke and cholangiocarcinoma research center, Khon Kaen University</organization>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Calcitriol</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

